% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Dick:125705,
      author       = {J. Dick and N. Lang and A. Slynko$^*$ and A.
                      Kopp-Schneider$^*$ and C. Schulz and A.
                      Dimitrakopoulou-Strauss$^*$ and A. H. Enk and J. C. Hassel},
      title        = {{U}se of {LDH} and autoimmune side effects to predict
                      response to ipilimumab treatment.},
      journal      = {Immunotherapy},
      volume       = {8},
      number       = {9},
      issn         = {1750-7448},
      address      = {London},
      publisher    = {Future Medicine Ltd},
      reportid     = {DKFZ-2017-01831},
      pages        = {1033 - 1044},
      year         = {2016},
      abstract     = {Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody
                      that enhances T-cell activity and proliferation.In a
                      retrospective analysis of 86 patients the clinical benefits
                      of ipilimumab treatment were correlated with laboratory and
                      clinical data.A lactate dehydrogenase (LDH) value within the
                      normal range before the start of therapy was significantly
                      correlated with better OS (p ≤ 0.009). An increase in LDH
                      level after two cycles was indicative of a poor outcome, and
                      was significantly negatively correlated with treatment
                      response and overall survival and progression-free survival.
                      $42\%$ of all patients suffered from autoimmune toxicity
                      (CTCAE grades 2-4). The occurrence of autoimmune toxicity
                      clearly correlated with clinical benefit.Changes in LDH
                      level and side effects correlate with response to therapy
                      and survival.},
      keywords     = {Antibodies, Monoclonal (NLM Chemicals) / Biomarkers,
                      Pharmacological (NLM Chemicals) / CTLA-4 Antigen (NLM
                      Chemicals) / ipilimumab (NLM Chemicals) / C-Reactive Protein
                      (NLM Chemicals) / L-Lactate Dehydrogenase (NLM Chemicals)},
      cin          = {C060 / E060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)E060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27485076},
      doi          = {10.2217/imt-2016-0083},
      url          = {https://inrepo02.dkfz.de/record/125705},
}